Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Diagnosing the Extent of Disease in Patients With Prostate Cancer
Prostate Cancer
About this trial
This is an interventional diagnostic trial for Prostate Cancer focused on measuring adenocarcinoma of the prostate, stage I prostate cancer, stage IIB prostate cancer, stage IIA prostate cancer
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically confirmed stage I-II adenocarcinoma of the prostate At least 6 weeks since prior biopsy Scheduled to undergo radical prostatectomy within 6 months of MRI and magnetic resonance spectroscopic imaging (MRSI) PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Cardiovascular: No cardiac pacemakers Other: Must be willing and able to undergo MRI/MRSI No allergy to latex No contraindications to MRI such as non-compatible intracranial vascular clips No metallic hip implant or any other metallic implant or device that would compromise quality of MRI/MRSI No contraindications to or intolerance of endorectal coil insertion (e.g., prior abdominoperineal resection of the rectum or Crohn's disease) No general medical or psychiatric condition or physiologic status unrelated to prostate cancer that would preclude valid informed consent PRIOR CONCURRENT THERAPY: Biologic therapy: No prior BCG for bladder cancer Chemotherapy: Not specified Endocrine therapy: No prior androgen-deprivation therapy Radiotherapy: No prior prostatic or rectal radiotherapy Surgery: See Disease Characteristics No prior cryosurgery No prior surgery for prostate cancer No prior transurethral resection of the prostate (TURP) No prior rectal surgery Other: No prior complementary alternative medicine
Sites / Locations
- UCSF Comprehensive Cancer Center
- Yale Comprehensive Cancer Center
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Brigham and Women's Hospital
- Mayo Clinic Cancer Center
- Memorial Sloan-Kettering Cancer Center
- Abramson Cancer Center of the University of Pennsylvania
- M.D. Anderson Cancer Center at University of Texas